van Damme P - Search Results

1

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.

Vesikari T, Langley JM, Segall N, Ward BJ, Cooper C, Poliquin G, Smith B, Gantt S, McElhaney JE, Dionne M, van Damme P, Leroux-Roels I, Leroux-Roels G, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson DE, Popovic V, Diaz-Mitoma F; PROTECT Study Group. Vesikari T, et al. Among authors: van damme p. Lancet Infect Dis. 2021 Sep;21(9):1271-1281. doi: 10.1016/S1473-3099(20)30780-5. Epub 2021 May 11. Lancet Infect Dis. 2021. PMID: 33989539 Clinical Trial.

2

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team. Vesikari T, et al. Among authors: van damme p. N Engl J Med. 2006 Jan 5;354(1):23-33. doi: 10.1056/NEJMoa052664. N Engl J Med. 2006. PMID: 16394299 Free article. Clinical Trial.

3

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study.

Van Damme P, Moiseeva A, Marichev I, Kervyn AD, Booy R, Kuriyakose S, Brockway A, Ng SP, Leyssen M, Jacquet JM. Van Damme P, et al. BMC Infect Dis. 2010 Dec 20;10:357. doi: 10.1186/1471-2334-10-357. BMC Infect Dis. 2010. PMID: 21171982 Free PMC article. Clinical Trial.

4

Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age.

van Damme P, Kafeja F, Van Der Wielen M, Leyssen M, Jacquet JM. van Damme P, et al. Among authors: van der wielen m. Pediatr Infect Dis J. 2011 Aug;30(8):703-5. doi: 10.1097/INF.0b013e3182138296. Pediatr Infect Dis J. 2011. PMID: 21346683

5

Hepatitis B and the need for a booster dose.

Leuridan E, Van Damme P. Leuridan E, et al. Among authors: van damme p. Clin Infect Dis. 2011 Jul 1;53(1):68-75. doi: 10.1093/cid/cir270. Clin Infect Dis. 2011. PMID: 21653306

6

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.

Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Van Damme P, et al. Among authors: van der meeren o. Vaccine. 2011 Aug 11;29(35):5932-9. doi: 10.1016/j.vaccine.2011.06.049. Epub 2011 Jun 28. Vaccine. 2011. PMID: 21718738 Clinical Trial.

7

Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years.

Van Herck K, Jacquet JM, Van Damme P. Van Herck K, et al. Among authors: van damme p. J Med Virol. 2011 Nov;83(11):1885-91. doi: 10.1002/jmv.22200. Epub 2011 Aug 23. J Med Virol. 2011. PMID: 21915861

8

Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine.

Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Van Herck K, et al. Among authors: van damme p. Hum Vaccin Immunother. 2012 Mar;8(3):323-7. doi: 10.4161/hv.18617. Epub 2012 Feb 13. Hum Vaccin Immunother. 2012. PMID: 22327499 Clinical Trial.

9

Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery.

Hendrickx G, Vorsters A, Van Damme P. Hendrickx G, et al. Among authors: van damme p. Curr Opin Infect Dis. 2012 Oct;25(5):578-83. doi: 10.1097/QCO.0b013e328357e65c. Curr Opin Infect Dis. 2012. PMID: 22907280 Review.

10

Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.

Van Damme P, Kafeja F, Bambure V, Hanon E, Moris P, Roman F, Gillard P. Van Damme P, et al. Hum Vaccin Immunother. 2013 Jul;9(7):1512-22. doi: 10.4161/hv.24504. Epub 2013 Apr 9. Hum Vaccin Immunother. 2013. PMID: 23571166 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,227 results

Search Page